Radioimmunotherapy combined with antibody–drug conjugate-induced radiosensitization leads to long-term remission of mycosis fungoides
We evaluated a combination of brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam therapy in 14 patients with tumour-stage mycosis fungoides (MF). The overall response rate was 100%, with 64% of patients achieving complete remission; treatment was well tolerated, with limited toxicity. Translational analyses indicated synergistic activity, evidenced by increased CD30 expression and tumour cell death, supporting this approach as a promising treatment option for MF.
Authors
- Kathrin A. Brücksken
- Marjan Motiei (ORCID: https://orcid.org/0000-0002-5453-2630)
- Michael Daum-Marzian
- Khaled Elsayad (ORCID: https://orcid.org/0000-0001-9303-7336)
- Mathias Oymanns (ORCID: https://orcid.org/0000-0003-4719-3201)
- B. Greve
- Assaf Chalid
- Hans T Eich
- Raed Abu-Dawud
- David R Steinke
Institutions
- Philipps University of Marburg (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE)
- Helios Klinikum Krefeld (DE)
- University Hospital Münster (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1093/bjd/ljaf521
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00